← Back to Cancer Screening

Signatera by Natera

Cancer patients monitoring for recurrence

Variable
FDA approved (MRD)
Detects: Patient-specific
Sample: Blood draw
Results: 3-7 days

Test Performance

Sensitivity

Varies by cancer

Specificity

>99.8%

Detection Method

ctDNA (personalized)

Turnaround

3-7 days

Key Features

Personalized cancer monitoring • Detects recurrence early • Treatment response tracking • Tumor-informed approach

Who It's For

Important Notes

Not for initial detection - used for monitoring known cancer patients. Very high specificity for recurrence.

Learn more about Signatera by Natera

Discuss with your physician before ordering.

Visit Signatera by NateraCompare All